On Tuesday, Shares of PNC Financial Services Group Inc (NYSE:PNC), gained 0.57% to $87.85.
Harris Williams & Co., a preeminent middle market investment bank focused on the advisory needs of clients worldwide, releases proprietary research about M&A conducted as part of an exclusive partnership with Inc., the only major media brand dedicated exclusively to owners and managers of growing private companies. The study, fielded by Inc. and Harris Williams & Co., surveyed nearly 700 CEOs and top executives of privately held, high growth companies that have been recognized on the Inc. 5000 lists. The research provides insight into middle market companies across a wide range of industries about near-term plans for M&A. The results show that about 81% of survey respondents are interested in M&A over the next three years. The majority of respondents, 52%, indicated that they anticipate to sell their business, but only 25% presently have a detailed exit strategy in place. Please click here to review the full white paper analyzing the research results, which is published on Harris Williams & Co.’s website.
“The research findings provide a deeper understanding of the drivers of M&A for growing companies and hopes and fears administration teams have about selling or acquiring a business,” said Hiter Harris, a managing director and co-founder of Harris Williams & Co. “Our firm has a long history of advising leading middle market companies, many of whom have been recognized on Inc. 5000 lists. Conducting this research with Inc. allows us to provide relevant insight and perspective as a resource to business leaders, investors and buyers.”
The PNC Financial Services Group, Inc. operates as a diversified financial services company in the United States. It operates through six segments: Retail Banking, Corporate & Institutional Banking, Asset Administration Group, Residential Mortgage Banking, BlackRock, and Non-Planned Assets Portfolio.
Shares of Prudential Financial Inc (NYSE:PRU), inclined 0.63% to $75.01, during its last trading session.
Prudential Financial, Inc., officially opened its new office tower at a ribbon cutting attended by John Strangfeld, chairman and CEO of Prudential, Cory Booker, U.S. Senator from N.J., Ras Baraka, Mayor of Newark, Donald Payne, Jr., U. S. Representative from New Jersey, Kim Guadagno, Lieutenant Governor and Secretary of State of N.J., and many more dignitaries from the surrounding Newark area.
Located at 655 Broad Street and designed by Kohn Pedersen Fox, the 740,000-square-foot, 20-story building is the workplace of nearly 3,000 Prudential employees and has expanded the company’s Newark campus. The new tower is located two blocks from Prudential’s global corporate headquarters at 751 Broad Street and three blocks from its Washington Street building.
Prudential Financial, Inc. provides insurance, investment administration, and other financial products and services to individual and institutional customers in the United States and internationally.
At the end of Tuesday’s trade, Shares of Darden Restaurants, Inc. (NYSE:DRI), lost -0.32% to $67.89.
Darden Restaurants, stated its financial results for the first quarter ended August 30, 2015.
First Quarter 2016 Financial Highlights As Compared To Same Fiscal Quarter Last Year
- Total sales from ongoing operations raised 5.7% to $1.69 billion
- Adjusted earnings per diluted share from ongoing operations raised 112.5% to $0.68*
- On a stated basis, earnings per diluted share from ongoing operations were $0.63 and were negatively influenced by about $0.05 related to the ongoing implementation of the Company’s planned real estate plan
- Net earnings were $86.4 million contrast to the $503.2 million last year, which comprised the gain on the sale of suspended operations
- Same-restaurant sales raised 3.4% for the quarter
Darden Restaurants, Inc., through its auxiliaries, owns and operates full-service restaurants in the United States and Canada. As of July 8, 2015, it owned and operated about 1,500 restaurants under the Olive Garden, LongHorn Steakhouse, Bahama Breeze, Seasons 52, The Capital Grille, Eddie V’s, and Yard House brand names. The company was founded in 1968 and is headquartered in Orlando, Florida.
Finally, Neurocrine Biosciences, Inc. (NASDAQ:NBIX), ended its last trade with 1.30% gain, and closed at $35.80.
AbbVie, in cooperation with Neurocrine Biosciences, Inc. (NBIX), declared the completion of a Phase 2b clinical trial evaluating the safety and efficacy of elagolix alone or in combination with add-back therapy contrast to placebo. The trial was conducted in women with heavy menstrual bleeding (HMB) associated with uterine fibroids. Preliminary results showed that all of the elagolix treatment arms, with and without add-back therapy, reduced heavy menstrual bleeding as contrast to placebo.
Uterine fibroids (also called leiomyomas or myomas) are noncancerous muscle tissue tumors of the uterus.1 Fibroids are most common in women aged 30-40 years but can occur at any age. They can range in size from nearly undetectable to bulky masses that can distort the uterus. Fibroids can be asymptomatic but in some women cause symptoms such as: longer, more frequent, or heavy menstrual bleeding; menstrual pain; vaginal bleeding at time other than menstruation; pain in the abdomen or lower back; pain during sex; difficulty urinating; frequent urination; constipation or rectal pain.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, in addition to Phase I study for tourette syndrome.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
